Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy

Abstract

Patient and treatment characteristics can be used to predict hearing level after concomitant chemoradiotherapy for head and neck cancer. This step may constitute the first in evidence-based individual counseling for treatment-induced hearing loss.